Company Description
From Hopis to hope, from kachinas to clones (cloned cells, that is), the company formerly known as A.C.T. Holdings was until late 2004 known as...
Key Advanced Cell Technology Financials
| Company Type | Public - OTC: ACTC Main Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2007 Sales (mil.) | $0.6 |
| Employees | -- |
More Advanced Cell Technology Financials (4 pages)
Competition
Competitive Landscape for Biotechnology Sector
Demand for biotechnology products and services is driven primarily by the willingness of insurers to pay for new medical treatments. The profitability of individual companies depends on the...
Read more about Advanced Cell Technology's competition across multiple industries
Top Advanced Cell Technology Competitors
Editor-Selected Competitor List For Advanced Cell Technology
Sponsored Links
The Business Directory
Advanced Cell Technology Executives sponsored by genius.com
| Title | Name & Bio | Contact |
|---|---|---|
| Chairman and CEO | William M. (Bill) Caldwell IV | Network | E-mail |
More Advanced Cell Technology Executives
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Tools from our advertising partners:
Current Advanced Cell Technology News
- Transformed: The stem cell breakthrough [New Scientist]: The ability to turn any cell into a stem cell could be the first step to regenerating limbs and organs, as Peter Aldhous reports: Stem cell banks: Off-the-shelf cells: Peter Aldhous (03 May 2008 00:01:00 EDT)
- Genetic engineering [Statesman (India)] (25 Apr 2008 00:01:00 EDT)
- Scientists plan to create 'chimeras' in last-ditch bid to save rhinos T1 News [Independent] (18 Apr 2008 00:01:00 EDT)
Latest Industry Video
-
Rx For Cheap Drugs (4:04)
07/23/07 5:20PM ET - Miller Tabak & Co. Pharmaceuticals Analyst Les Fundleyder and Bain & Company Partner Tim Van Biesen discuss patent expirations affecting U.S. drug costs.